Affiliations
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
- University of the Chinese Academy of Sciences, Beijing, China.
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
- CAS Key Laboratory of Molecular Virology & Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
- Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
- College of Life Sciences, Nanjing Normal University, Nanjing, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Hubei Jiangxia Laboratory, Wuhan, China.
PMID: 37917215 PMCID: PMC10795836 DOI: 10.1172/jci.insight.175461
Abstract
Background: Nipah virus (NiV) is a bat-borne paramyxovirus causing neurological and respiratory diseases with high mortality. Developing vaccines to prevent NiV infection is essential.
Methods: The study designed an F protein sequence using bioinformatics and developed a chimpanzee adenoviral vector and DNA vaccines. The vaccine efficacy was tested in mice and hamsters.
Results: Vaccinated hamsters survived NiV-M and NiV-B strains without clinical signs, showing complete protection and virus clearance in different tissues.
Conclusions: The vaccine has the potential to provide broad-spectrum protection against NiV strains.
Keywords
Adaptive immunity; Vaccines; Virology.
